Department of Clinical Pharmacy, School of Preclinical Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Department of Clinical Pharmacy, School of Preclinical Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Clin Immunol. 2022 May;238:109013. doi: 10.1016/j.clim.2022.109013. Epub 2022 Apr 15.
Short-chain fatty acids (SCFAs), metabolites of intestinal microorganisms, have been linked to the occurrence and development of a variety of disorders, including cardiovascular disease (CVD), which is frequently accompanied by a sustaining inflammatory response and aberrant angiogenesis. Accumulating evidence from the study emphasizes that SCFAs are closely connected with the activation of the NLRP3 inflammasome (NACHT, LRR, and PYD domains-containing protein 3) and the process of angiogenesis. This review summarizes emerging literature on the impact of SCFAs on various physiological processes, with a subtle attention on the interaction between SCFAs and CVD (especially atherosclerosis, myocardial infarction, and hypertension), SCFAs and NLRP3 inflammasome, as well as SCFAs and angiogenesis. As a result, we speculate that it is convincing that SCFAs play a mediating role in the microbiota-inflammasome-angiogenesis-CVD axis, opening up a new horizon to investigate the function or level of SCFAs as a therapeutic strategy for CVD.
短链脂肪酸（SCFAs）是肠道微生物的代谢产物，与多种疾病的发生和发展有关，包括心血管疾病（CVD），CVD 通常伴随着持续的炎症反应和异常的血管生成。越来越多的研究证据强调，SCFAs 与 NLRP3 炎性体（NACHT、LRR 和 PYD 结构域包含蛋白 3）的激活和血管生成过程密切相关。本综述总结了关于 SCFAs 对各种生理过程影响的新文献，特别关注 SCFAs 与 CVD（特别是动脉粥样硬化、心肌梗死和高血压）、SCFAs 与 NLRP3 炎性体以及 SCFAs 与血管生成之间的相互作用。因此，我们推测 SCFAs 在微生物群-炎性体-血管生成-CVD 轴中发挥介导作用是有说服力的，为研究 SCFAs 的功能或水平作为 CVD 的治疗策略开辟了新的视野。
